Axsome Therapeutics, Inc. (AXSM) is approaching a critical milestone, with the FDA set to deliver its verdict tomorrow, April 30, 2026, on the supplemental New Drug Application (sNDA) for AXS-05 in Alzheimer's disease agitation.
AXS-05 is a fixed-dose combination of dextromethorphan and bupropion. Dextromethorphan is widely known as the active ingredient in cough medicines, while bupropion is prescribed for depression and smoking cessation.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.